Sun Pharmaceutical's LEQSELVI (deuruxolitinib) receives US FDA approval for severe alopecia areata treatment in adults.
Sun Pharmaceutical's LEQSELVI (deuruxolitinib), an oral JAK inhibitor, has received US FDA approval for treating severe alopecia areata in adults. The approval is based on data from two Phase 3 clinical trials, where one-third of patients experienced 80% scalp hair coverage after 24 weeks of treatment. Alopecia areata affects around 700,000 people in the US, with 300,000 experiencing severe forms of the condition.
July 26, 2024
5 Articles